#Vitamin D #Dermocosmetics #Solaana MD

Solaana MD: A New Frontier in Dermocosmetics

In a significant development within the skincare industry, GTT Group has announced the exclusive representation for the acquisition of Solaana MD, an innovative dermocosmetics brand that is set to transform the market landscape. Founded by medical professionals, Solaana MD has developed a patented high-absorption topical Vitamin D delivery system that caters to a critical gap in the skincare sector—Vitamin D deficiency.

Addressing a Vital Need

The skincare industry has unintentionally created a dilemma for consumers. With increasing awareness of sun exposure risks, the daily use of sunscreen has become a global norm, leading to reduced natural Vitamin D synthesis in our skin. This situation affects up to 40% of adults in the U.S., creating an urgent need for effective vitamin supplementation, particularly for those with chronic skin conditions such as eczema and psoriasis, which affect more than 30 million Americans.

Solaana MD's unique formulation allows for transdermal delivery of Vitamin D, effectively bypassing the digestive system. This feature not only enhances consumer convenience but also ensures localized Vitamin D availability directly at the skin surface, making it a versatile addition to daily skincare routines.

A Turnkey Opportunity

The acquisition of Solaana MD represents a pivotal opportunity for companies aiming to expand their portfolios in the rapidly growing $76 billion dermocosmetics market. Tyler McKinley, Managing Director of GTT Group, emphasizes the brand's potential: “Solaana MD is a strategic imperative for any beauty or pharmaceutical company looking to fortify their position in skincare backed by science.